UPM Acquires Former Pfizer Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

UPM Acquires Former Pfizer Facility
Pfizer had gained the facility through its previous acquisition of King Pharmaceuticals.


UPM Pharmaceuticals, a Baltimore, Maryland-based drug development and contract manufacturer, will be acquiring the 500,000-ft2 commercial manufacturing facility that Pfizer currently operates in Bristol, Tennessee.

The acquisition of the Pfizer facility will provide UPM with large-scale commercial capabilities for manufacturing and packaging of solid oral dosage tablets and capsules as well as semisolid manufacturing of creams and ointments. The facility will also provide for technology-transfer support, pilot-plant scale-up capabilities, analytical and microbial testing as well as dedicated suites for potent compounds. As part of the purchase, UPM will continue to manufacture Pfizer’s current portfolio of products within the facility for two years. The new facility will give UPM the capability to annually produce 3.5 billion tablets and 680 million capsules.

Pfizer gained the facility as part of its acquisition of King Pharmaceuticals, a deal which was announced in late 2010 and completed in early 2011. King Pharmaceuticals was founded by UPM’s current Chairman and CEO John Gregory.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here